UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 | Other Events |
Second Sight Medical Products, Inc. (the “Company”) was notified on July 14, 2022, that the National Institutes of Health (“NIH”) released year four funding in the amount of $1.1 million of the $6.4 million planned five-year grant, 5UH3NS103442. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Early Feasibility Clinical Trial of a Visual Cortical Prosthesis. The Company issued a press release entitled Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study, which is attached to this Current Report as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
Description | ||
99.1 | Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study dated July 18, 2022. | ||
104 | The cover page of this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SECOND SIGHT MEDICAL PRODUCTS, INC. | ||
Date: July 18, 2022 | By: | /s/ Scott Dunbar |
Scott Dunbar | ||
Acting Chief Executive Officer |
Exhibit 99.1
FOR IMMEDIATE RELEASE
Second
Sight Medical Products Announces Year Four NIH
Funding of its Orion Study
Grant proceeds support an ongoing early feasibility study of Orion
Los Angeles, CA – (BUSINESS NEWSWIRE) – July 18, 2022 – Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (“NIH”) of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the “Orion Trial”), grant 5UH3NS103442. The NIH released $1.1 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial. The funding supports continuation of this important research and testing of the Orion Visual Cortical Prosthesis.
About the Orion Visual Cortical Prosthesis System
Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of patterns of light. An early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.
About Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prostheses that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company’s headquarters are in Los Angeles, California. More information is available at secondsight.com. On February 4, 2022, Second Sight entered into a merger agreement with Nano Precision Medical, Inc. (“NPM”), and, following approval by shareholders of the Company, anticipates concluding the merger in August 2022.
Safe Harbor
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “intended” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this press release regarding the amount of NIH grant proceeds expected to be received. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Second Sight’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) legal claims or proceedings relating to Second Sight’s termination of the Memorandum of Understanding with Pixium Vision and costs relating thereto; (2) changes in applicable laws or regulations; (3) the possibility that Second Sight may be adversely affected by other economic, business, and/or competitive factors; (4) the impact of COVID-19 on Second Sight’s business; (5) the possibility that shareholders of the Company may not approve the merger with NPM or that the merger may not be completed for any other reason; and (6) various other risks and uncertainties. Some of these risks and uncertainties may in the future be amplified by the COVID-19 outbreak, including subvariants thereof and there may be additional risks that Second Sight considers immaterial or which are unknown. A further list and description of risks and uncertainties can be found in Second Sight’s Annual Report on Form 10-K filed on March 29, 2022, and in the Company’s Forms 10-K/A filed on May 2, 2022, S-4 filed on May 13, 2022, and 10-Q filed on May 16, 2022, and as thereafter amended. Any forward-looking statement made by us in this press release is based only on information currently available to Second Sight and speaks only as of the date on which it is made. Second Sight undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Additional Information and Where to Find It
This communication, among other things, relates to a proposed business combination of the Company and NPM. The Company filed the registration statement on Form S-4 with the Securities and Exchange Commission (the “SEC”), which included a document that serves as a prospectus and proxy statement of the Company. The SEC declared the registration statement effective on June 24, 2022, and the proxy statement/prospectus was first mailed to shareholders of the Company on or about June 29, 2022. The proxy statement/prospectus described above contains important information about the Company, NPM, proposed merger, and related matters. This communication is not a substitute for the proxy statement/prospectus described above. Investors and securityholders are urged to carefully read the proxy statement/prospectus and all other relevant documents filed by the Company with the SEC because they contain important information about the merger and related matters. All documents are available free of charge at the SEC’s website (www.sec.gov). You may also obtain these documents by contacting Company’s Investor Relations department at investors@secondsight.com.
Participants of Solicitation
The Company and its respective directors and executive officers may be deemed to be participants in any solicitation of proxies in connection with the proposed merger. Information about the Company’s directors and executive officers is available in the Company’s Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2021. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the proxy statement/prospectus and all other relevant materials filed with the SEC regarding the proposed merger when they become available. This document is available from the Company free of charge as described in the preceding paragraph.
Company Contact:
Scott Dunbar
Acting CEO
investors@secondsight.com
(818) 833-5000
Investor Relations Contact:
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
Dave@redchip.com
Cover |
Jul. 14, 2022 |
---|---|
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 14, 2022 |
Entity File Number | 001-36747 |
Entity Registrant Name | SECOND SIGHT MEDICAL PRODUCTS, INC. |
Entity Central Index Key | 0001266806 |
Entity Tax Identification Number | 02-0692322 |
Entity Incorporation, State or Country Code | CA |
Entity Address, Address Line One | 13170 Telfair Ave |
Entity Address, City or Town | Sylmar |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 91342 |
City Area Code | (818) |
Local Phone Number | 833-5000 |
Written Communications | true |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Common Stock [Member] | |
Title of 12(b) Security | Common Stock |
Trading Symbol | EYES |
Security Exchange Name | NASDAQ |
Warrants [Member] | |
Title of 12(b) Security | Warrants |
Trading Symbol | EYESW |
Security Exchange Name | NASDAQ |
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